Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMABNASDAQ:ITCINYSE:RDYNASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMABGenmab A/S$21.48+2.6%$20.33$17.24▼$30.41$13.77B1.071.06 million shs1.49 million shsITCIIntra-Cellular Therapies$131.87$131.49$64.09▼$131.98$14.05B0.691.48 million shsN/ARDYDr. Reddy's Laboratories$14.00+1.2%$13.23$12.26▼$16.89$11.69B0.511.48 million shs1.24 million shsRYTMRhythm Pharmaceuticals$64.01+0.3%$56.09$35.17▼$68.58$4.07B2.36548,111 shs475,184 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMABGenmab A/S+2.63%+4.32%+14.13%+9.20%-25.29%ITCIIntra-Cellular Therapies0.00%0.00%-0.03%+3.77%+81.31%RDYDr. Reddy's Laboratories+1.12%+1.38%+5.66%+1.19%-5.42%RYTMRhythm Pharmaceuticals+0.33%+0.39%+23.19%+7.71%+54.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGMABGenmab A/S4.4503 of 5 stars4.35.00.00.03.30.03.1ITCIIntra-Cellular Therapies0.9174 of 5 stars1.10.00.04.51.11.70.6RDYDr. Reddy's Laboratories1.7388 of 5 stars2.32.01.70.02.80.01.3RYTMRhythm Pharmaceuticals3.7807 of 5 stars3.51.00.04.33.30.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMABGenmab A/S 2.69Moderate Buy$39.1782.34% UpsideITCIIntra-Cellular Therapies 2.17Hold$109.70-16.81% DownsideRDYDr. Reddy's Laboratories 2.50Moderate Buy$17.0021.43% UpsideRYTMRhythm Pharmaceuticals 3.00Buy$74.9217.05% UpsideCurrent Analyst Ratings BreakdownLatest RYTM, ITCI, GMAB, and RDY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025GMABGenmab A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $37.004/8/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.004/8/2025RYTMRhythm PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$81.00 ➝ $92.004/8/2025RYTMRhythm PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $80.004/7/2025RYTMRhythm PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$80.00 ➝ $91.004/7/2025RYTMRhythm PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$63.00 ➝ $63.004/2/2025ITCIIntra-Cellular TherapiesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$132.00 ➝ $132.004/1/2025GMABGenmab A/SSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform ➝ Underperform3/24/2025RYTMRhythm PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.003/18/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$64.00 ➝ $66.003/11/2025GMABGenmab A/STruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $45.00(Data available from 5/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMABGenmab A/S$21.53B0.64$1.45 per share14.80$8.04 per share2.67ITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44RDYDr. Reddy's Laboratories$311.31B0.04$1.06 per share13.25$4.50 per share3.11RYTMRhythm Pharmaceuticals$130.13M31.28N/AN/A$2.87 per share22.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMABGenmab A/S$1.14B$1.7412.3412.072.6536.30%16.78%13.79%5/8/2025 (Estimated)ITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%5/6/2025 (Estimated)RDYDr. Reddy's Laboratories$668M$0.6322.2917.07N/A17.25%17.87%12.32%5/6/2025 (Estimated)RYTMRhythm Pharmaceuticals-$184.68M-$4.35N/AN/AN/A-230.07%-367.36%-77.47%5/7/2025 (Estimated)Latest RYTM, ITCI, GMAB, and RDY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025GMABGenmab A/S$0.26N/AN/AN/A$5.17 billionN/A5/7/2025Q1 2025RYTMRhythm Pharmaceuticals-$0.67N/AN/AN/A$40.43 millionN/A5/6/2025Q4 24/25RDYDr. Reddy's Laboratories$0.20N/AN/AN/A$83.70 billionN/A2/26/2025Q4 2024RYTMRhythm Pharmaceuticals-$0.69-$0.72-$0.03-$0.72$38.48 million$41.83 million2/21/2025Q4 2024ITCIIntra-Cellular Therapies-$0.08-$0.16-$0.08-$0.16$205.08 million$199.22 million2/12/2025Q4 2024GMABGenmab A/S$0.28$0.57+$0.29$0.85$884.02 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMABGenmab A/SN/AN/AN/AN/AN/AITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$0.080.57%N/A12.70%N/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMABGenmab A/SN/A5.255.24ITCIIntra-Cellular TherapiesN/A7.667.51RDYDr. Reddy's Laboratories0.021.921.38RYTMRhythm PharmaceuticalsN/A3.493.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMABGenmab A/S7.07%ITCIIntra-Cellular Therapies92.33%RDYDr. Reddy's Laboratories3.85%RYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipGMABGenmab A/S1.54%ITCIIntra-Cellular Therapies2.60%RDYDr. Reddy's Laboratories2.00%RYTMRhythm Pharmaceuticals5.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMABGenmab A/S1,660641.20 million651.58 millionOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableRDYDr. Reddy's Laboratories24,800834.77 million818.05 millionOptionableRYTMRhythm Pharmaceuticals14063.60 million58.02 millionOptionableRYTM, ITCI, GMAB, and RDY HeadlinesRecent News About These CompaniesVoya Investment Management LLC Sells 5,663 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 3 at 4:47 AM | marketbeat.comPDT Partners LLC Acquires 32,083 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 2 at 6:32 AM | marketbeat.comRhythm Pharmaceuticals (RYTM) Projected to Post Earnings on WednesdayMay 2 at 5:35 AM | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Sells $438,964.60 in StockMay 2 at 5:20 AM | insidertrades.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Bought by Price T Rowe Associates Inc. MDMay 2 at 4:36 AM | marketbeat.comFirst Trust Advisors LP Has $6.63 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 2 at 4:06 AM | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by LPL Financial LLCMay 2 at 3:09 AM | marketbeat.comDark Forest Capital Management LP Takes $292,000 Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 1 at 5:02 AM | marketbeat.comWill Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should KnowApril 30 at 11:06 AM | zacks.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Position Lifted by Lord Abbett & CO. LLCApril 30 at 5:48 AM | marketbeat.comArtia Global Partners LP Makes New $2.80 Million Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)April 29, 2025 | marketbeat.comNatixis Has $56,000 Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)April 28, 2025 | marketbeat.comWells Fargo & Company MN Boosts Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)April 28, 2025 | marketbeat.comBarclays PLC Has $7.58 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)April 26, 2025 | marketbeat.comLegal & General Group Plc Reduces Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)April 26, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $74.92 Average Target Price from AnalystsApril 26, 2025 | americanbankingnews.comRhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last?April 25, 2025 | zacks.comHood River Capital Management LLC Raises Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)April 25, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of "Buy" by BrokeragesApril 25, 2025 | marketbeat.comSilverarc Capital Management LLC Grows Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)April 24, 2025 | marketbeat.comDiadema Partners LP Buys New Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)April 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRYTM, ITCI, GMAB, and RDY Company DescriptionsGenmab A/S NASDAQ:GMAB$21.48 +0.55 (+2.63%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$21.50 +0.02 (+0.07%) As of 05/2/2025 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Intra-Cellular Therapies NASDAQ:ITCI$131.87 0.00 (0.00%) As of 04/2/2025Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Dr. Reddy's Laboratories NYSE:RDY$14.00 +0.17 (+1.23%) Closing price 05/2/2025 03:59 PM EasternExtended Trading$14.01 +0.01 (+0.10%) As of 05/2/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Rhythm Pharmaceuticals NASDAQ:RYTM$64.01 +0.21 (+0.33%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$62.76 -1.25 (-1.95%) As of 05/2/2025 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/28 - 05/02 Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Why Spotify Stock Still Has Room to Run in 2025 Is It Time to Load Up on Bond ETFs? Palantir Earnings: 1 Bullish Signal and 1 Area of Concern Roblox Stock Gains Momentum and Can Top $100 in 2025 Visa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
